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SUMMARY
Systemic fungal infections are responsible for high mortality rates. Several species of fungi may be involved, but Candida spp. is 
the most prevalent. Simvastatin is used to lower cholesterol and also exhibits antifungal action. The aim of this study was to evaluate 
the synergistic action of simvastatin with fluconazole against strains of Candida spp. Susceptibility testing was performed according 
to protocol M27-A3, by broth microdilution method and the synergistic effect of simvastatin and fluconazole was calculated based 
on FICI (Fractional Inhibitory Concentration Index). Eleven strains were evaluated, and simvastatin showed a synergistic effect with 
fluconazole against 10 (91%) of the Candida spp. strains tested. Simvastatin may be a valuable drug in the treatment of systemic 
infections caused by Candida spp.
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INTRODUCTION
Candidemias are fungal infections that have high mortality rates and 
are responsible for increased hospital costs1. The number of available 
antifungal agents for systemic use is rather limited, and isolation of strains 
of Candida spp. resistant to conventional antifungal drugs is increasingly 
common4. New therapeutic strategies are needed to prevent the spread of 
resistance. Among these strategies we can highlight the search for new 
drugs and drug combinations with synergistic purpose3,9. Statins are drugs 
used to treat hypercholesterolemia, but also have antifungal activity6. 
Simvastatin inhibits the enzyme 3-hydroxy-3-methylglutaryl reductase 
(HMG-CoA) and reduces the level of intermediates from cholesterol 
synthesis. Yeasts use the same enzymatic pathway, but the final product 
is ergosterol. In vitro studies have demonstrated that simvastatin inhibits 
the growth of species of Candida spp. and may be useful in the treatment 
of candidemias3,7,12.
The aim of this study was to evaluate the synergistic action between 
simvastatin and fluconazole against Candida spp. with elevated MICs 
for fluconazole.
MATERIALS AND METHODS
In all, 11 strains of Candida spp. were used (one C. albicans, five 
C. tropicalis, and five C. parapsilosis). The strains used were derived 
from clinical samples (nine from blood and two from urine). The strains 
were identified by biochemical, molecular and phenotypic methods11.
In this study, we tested the antifungal activity of simvastatin alone and 
in combination with fluconazole. Simvastatin (Sigma-USA) was activated 
in an ethanol solution of NaOH (15% (vol/vol) and 0.25% (m/vol) NaOH) 
at 60 °C for one hour9. The simvastatin solution was filtered and placed in a 
desiccator for 72 hours. Susceptibility testing was performed according to 
protocol M27-A3, by the RPMI broth microdilution method (Cultilab-São 
Paulo) (pH 7.0) buffered with MOPS (morpholinepropanesulfonic acid) 
(Sigma-USA)2. Fluconazole (Sigma-USA) and simvastatin were dissolved 
in water and butanol (Sigma-USA), respectively. To assess the synergistic 
potential of the drugs, the concentration of fluconazole was maintained 
unchanged at 4 μg/mL and simvastatin ranged from 0.25 to 128 μg/mL. 
The microdilution plates were incubated at 35 °C and read visually after 24 
hours and 48 hours of incubation. The MIC was considered as the lowest 
concentration of drugs that caused a 90% reduction in growth compared 
with the control strain. C. parapsilosis ATCC 22019 and C. krusei ATCC 
6258 were used as control strains. The synergistic effect of simvastatin 
and fluconazole was calculated based on FICI (Fractional Inhibitory 
Concentration Index). The data were interpreted according to the value of 
FICI: FICI ≤ 0.5-synergism (SYN); 0.5< FICI < 4.0 - indifference (IND); 
and FICI ≥ 4.0 - antagonism (ANT)10.
RESULTS
Table 1 shows the results of the FICIs (24h and 48h of incubation) 
for the strains tested. As can be verified, only one strain appeared as 
indifferent. In 10 strains, (91%) there was a strong synergistic effect 
demonstrated by the FICI calculation. FICI determination at 24 h 
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might be better than longer incubation periods in detecting significant 
pharmacodynamic interactions8. In our study there was no difference in 
comparing the results with 24 and 48 h of incubation.
We observed that when simvastatin was associated with fluconazole 
at a fixed concentration (4 μg/mL), there was a reduction of the MICs. 
Several studies show the interaction of statins with antifungals5,9.
DISCUSSION 
The FICI was ≤ 0.5, thus proving the synergy. LIU et al. (2009) 
observed that simvastatin inhibits the formation biofilm in C. albicans. 
These same authors observed that the probable mechanism of this action 
is due to the interference in the ergosterol cycle. In our study, we did not 
elucidate the mechanism of action, but hypothesized that the mechanism 
of action is due to the action at two distinct points of the ergosterol cycle.
In a study conducted with strains of C. albicans and C. glabrata, 
evaluating the synergism between simvastatin and fluconazole, an 
additive effect was observed9. In our study, the results were different; we 
found a synergistic effect. This discrepancy may be due to the fact that the 
strains used in our study were strains with elevated MICs for fluconazole.
Studies have shown the usefulness of statins in the treatment of fungal 
infections; however, more studies are needed to confirm the synergism5.
In our study, we showed that simvastatin has in vitro synergistic 
activity with fluconazole against strains with elevated MICs for 
fluconazole. Simvastatin may be a valuable drug to the treatment of 
fungal infections mainly caused by strains of Candida spp. resistant to 
fluconazole. However, we know these are preliminary data and that the 
dosage and duration of treatment in humans should be carefully studied. 
Therefore, it is important that further studies, such as molecular studies 
and animal tests, be made. This is the first study with strains that have 
a degree of resistance. We also know that future studies with a larger 
number of isolates and resistant isolates are of great importance. Our 
studies will continue in order to elucidate the mechanism of action and 
effects of simvastatin.
RESUMO
Sinergismo in vitro de sinvastatina e fluconazol  
contra espécies de Candida 
Infecções fúngicas sistêmicas são responsáveis por altas taxas de 
mortalidade. Várias espécies de fungos podem estar envolvidas, mas 
Candida spp é a mais prevalente. A sinvastatina é usada para diminuir 
o colesterol e também exibe ação antifúngica. O objetivo deste estudo 
foi avaliar a ação sinérgica de sinvastatina e fluconazol contra cepas de 
Candida spp. O teste de susceptibilidade foi realizado de acordo com o 
protocolo M27-A3, pelo método de micro diluição em caldo e o efeito 
sinérgico de sinvastatina e fluconazol foi calculado com base no ICIF 
(Índice de Concentração Inibitória Fraccionada). Onze cepas foram 
avaliadas, e a sinvastatina mostrou um efeito sinérgico com o fluconazol 
em dez (91%) das cepas de Candida spp. Sinvastatina pode ser uma droga 



















C. albicans 16 >128/ >128 <0.25/ 8 0.25/ 0.31 SYN
C. tropicalis 16 64/ >128 <0.25/ <0.25 0.25/ 0.25 SYN
C. tropicalis 8 64/ >128 <0.25/ <0.25 0.50/ 0.50 SYN
C. tropicalisu 8 >128/ >128 <0.25/ <0.25 0.50/ 0.50 SYN
C. tropicalisu 32 32/ >128 <0.25/ <0.25 0.13/ 0.13 SYN
C. tropicalis 32 >128/ >128 <0.25/ <0.25 0.13/ 0.13 SYN
C. parapsilosis 16 64/ 64 <0.25/ <0.25 0.25/ 0.25 SYN
C. parapsilosis 16 >128/ >128 <0.25/ <0.25 0.25/ 0.25 SYN
C. parapsilosis 8 >128/ >128 <0.25/ 0.50 0.50/ 0.5 SYN
C. parapsilosis 8 16/ >128 <0.25/ 16 0.52/ 0.63 IND
C. parapsilosis 16 >128/ >128 <0.25/ <0.25 0.25/ 0.25 SYN
a Yeast strains isolated from biological samples; u = urine, all other strains were isolated from blood.
b Flu - fluconazole (alone), Sim - simvastatin (alone). MIC was defined as the lowest concentration that produced 90% reduction in growth of fungal cells after 24 and 
48 hours of incubation. The procedure was performed according to CLSI protocol M27-A3. The concentration of fluconazole ranged from 0.125 to 64 μ/mL and the 
concentration of simvastatin ranged from 0.25 to 128 μg/mL.
c The concentration of fluconazole was maintained unchanged at (4 μg/mL) and simvastatin ranged from 128 to 0.25 μg/mL.
d The synergistic effect of fluconazole and simvastatin was calculated based on the FICI (Fractional Inhibitory Concentration Index (FICI=[FC]/CFS+[SC]/CSS), where 
[FC] and [SC] are the concentrations of fluconazole and of simvastatin that showed action when combined, [CFS] and [CSS] are the concentrations of the same drugs 
acting alone.
e The data were interpreted according to the FICI value. FICI ≤ 0.5-synergism (SYN); 0.5 < FICI ≤ 4.0 - indifference (IND); and FICI > 4.0 - antagonism (ANT).
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